Literature DB >> 34728073

Exposure to TNF inhibitors is rare at MOGAD presentation.

Vyanka Redenbaugh1, Eoin P Flanagan2, Valentina Floris3, Pietro Zara3, M Tariq Bhatti4, Francisco Sanchez4, Matthew Koster5, Sara Mariotto6, Sean J Pittock2, John J Chen4, Alberto Cauli7, Paolo Solla8, Elia Sechi9.   

Abstract

Entities:  

Keywords:  Adverse event; Demyelination; MOGAD; Myelin oligodendrocyte glycoprotein; Tumor necrosis factor

Mesh：

Substances：

Year:  2021        PMID： 34728073     DOI： 10.1016/j.jns.2021.120044

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


× No keyword cloud information.
  2 in total

Review 1.  Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management.

Authors:  Elia Sechi; Laura Cacciaguerra; John J Chen; Sara Mariotto; Giulia Fadda; Alessandro Dinoto; A Sebastian Lopez-Chiriboga; Sean J Pittock; Eoin P Flanagan
Journal:  Front Neurol       Date:  2022-06-17       Impact factor: 4.086

Review 2.  Drug-related immune-mediated myelopathies.

Authors:  David Gritsch; Cristina Valencia-Sanchez
Journal:  Front Neurol       Date:  2022-09-29       Impact factor: 4.086
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.